Roquefort Therapeutics (LON:COIL) Shares Up 7.9% – Here’s Why

Posted by on May 20th, 2026

Roquefort Therapeutics plc (LON:COIL – Get Free Report) shares shot up 7.9% during trading on Monday . The stock traded as high as GBX 8.90 and last traded at GBX 8.90. 314,041 shares changed hands during mid-day trading, an increase of 74% from the average session volume of 180,045 shares. The stock had previously closed at GBX 8.25.

Roquefort Therapeutics Stock Performance

The company has a market cap of £46.84 million, a P/E ratio of -1.75 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The company has a 50 day moving average price of GBX 8.78 and a 200-day moving average price of GBX 12.

Roquefort Therapeutics (LON:COIL – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported GBX (2.19) EPS for the quarter. Roquefort Therapeutics had a negative return on equity of 18.30% and a negative net margin of 57,057.07%.

About Roquefort Therapeutics

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.

Featured Stories

Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.